Search Results

You are looking at 181 - 190 of 512 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma

Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung

greater number of patients will be unable to complete the intended course of adjuvant therapy for similar reasons. 7 , 8 The administration of chemotherapy with or without radiation therapy (RT) before surgical resection is an alternative strategy that

Full access

Role of Adjuvant and Posttreatment Exercise Programs in Breast Health

Jennifer A. Ligibel

the completion of adjuvant therapy. Thus, physical activity has been shown to have several benefits for patients with breast cancer both during and after adjuvant therapy. No clear consensus exists on the “best” type of physical activity, but

Full access

The Challenges of Colorectal Cancer Survivorship

Crystal S. Denlinger and Andrea M. Barsevick

Edited by Kerrin G. Robinson

Fleming T Macdonald J . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma . N Engl J Med 1990 ; 322 : 352 – 358 . 7 de Gramont A Boni C Navarro M . Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy

Full access

NCCN Guidelines Updates: Breast Cancer

Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar

for advanced hormone-sensitive breast cancer at the NCCN 23rd Annual Conference. New Adjuvant Therapy Options for Patients With HER2-Positive Cancer Two new adjuvant treatment options for patients with HER2-positive disease are in the 2018 NCCN

Full access

NCCN Guidelines Updates: Breast Cancer

Melinda L. Telli, William J. Gradishar, and John H. Ward

personalize systemic adjuvant therapy choices,” Dr. Ward said. “The available assays have strong prognostic capability, and more data on this are coming.” Among the available assays are the 21-gene panel (Oncotype Dx), the 70-gene panel (MammaPrint), the 50

Full access

Uterine Neoplasms

Benjamin E. Greer, Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Patricia J. Eifel, Warner K. Huh, Wainwright Jaggernauth, Daniel S. Kapp, John J. Kavanagh, John R. Lurain III, Mark Morgan, Robert J. Morgan Jr, C. Bethan Powell, Steven W. Remmenga, R. Kevin Reynolds, Angeles Alvarez Secord, William Small Jr, and Nelson Teng

in endometrial carcinoma: overview of randomised trials . Clin Oncol (R Coll Radiol) 2008 ; 20 : 463 – 469 . 56 Fleming G . Adjuvant therapy for high-risk adenocarcinoma of the uterus . ASCO Educational Book 2008 : 230 – 233

Full access

Pancreatic Adenocarcinoma

Margaret A. Tempero, J. Pablo Arnoletti, Stephen Behrman, Edgar Ben-Josef, Al B. Benson III, Jordan D. Berlin, John L. Cameron, Ephraim S. Casper, Steven J. Cohen, Michelle Duff, Joshua D.I. Ellenhorn, William G. Hawkins, John P. Hoffman, Boris W. Kuvshinoff II, Mokenge P. Malafa, Peter Muscarella II, Eric K. Nakakura, Aaron R. Sasson, Sarah P. Thayer, Douglas S. Tyler, Robert S. Warren, Samuel Whiting, Christopher Willett, and Robert A. Wolff

pancreatic cancer, then surgical consultation is recommended. Restaging with high-quality abdominal and chest imaging is also recommended after surgery for resectable disease and before initiation of adjuvant therapy (see page 980). It should also be

Full access

Central Nervous System Cancers, Version 1.2015

Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Paul Brown, Nicholas Butowski, Marc C. Chamberlain, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Jona Hattangadi-Gluth, Matthias Holdhoff, Larry Junck, Thomas Kaley, Ronald Lawson, Jay S. Loeffler, Mary P. Lovely, Paul L. Moots, Maciej M. Mrugala, Herbert B. Newton, Ian Parney, Jeffrey J. Raizer, Lawrence Recht, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, David Tran, Nam Tran, Frank D. Vrionis, Stephanie Weiss, Patrick Yung Wen, Nicole McMillian, and Anita M. Engh

retrospective and phase II studies showing positive outcomes in patients who had partial resection or biopsy. 28 – 30 These data showing clinical activity of PCV as adjuvant therapy for newly diagnosed low-grade gliomas prompted a multicenter phase III

Full access

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Courtney Smith

modalities may be used, including radical cystectomy with or without neoadjuvant or adjuvant therapy, partial cystectomy, bladder-preserving approaches, and systemic therapy for advanced disease. Clinical trials investigating new treatments and further

Full access

Controversies in the Evaluation and Management of Atypical Melanocytic Proliferations in Children, Adolescents, and Young Adults

Damon Reed, Ragini Kudchadkar, Jonathan S. Zager, Vernon K. Sondak, and Jane L. Messina

observation and serial ultrasonography in selected cases. 59 Role for Adjuvant Therapies in Pediatric Patients With Node-Positive AMP In the United States, high-dose interferon alfa-2b (HDI) and pegylated interferon alfa-2b are the only approved